|Articles|April 1, 2022

Top 5 Infectious Disease Stories of the Week-April 1, 2022

Here is a rundown of the most popular stories we covered this past week.


Here is an opportunity to catch-up with some of the important stories we have been covering this week.

Contagion compiles 5 highlights of our coverage in infectious disease including video interviews, podcasts, and significant stories from the week ending April 1, 2022.

Here are Contagion’s highlights from the week:

1. First Study to Estimate Life Expectancy After COVID-19 Pandemic Finds 2 Years Lost
The coronavirus pandemic caused the first global recorded decline in human life expectancy.


2. Pfizer-BioNTech and Moderna mRNA Vaccines Elicit Different Antibody Responses
 The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.

3. FDA Amends Authorization for Second Booster Dose for mRNA COVID-19 Vaccines
The new action by the federal agency now means the additional booster shot can be administered to people 50 years and older.


4. NIH Launches Trial Evaluating Second COVID-19 Booster Shots
One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.


5. Sotrovimab Distribution Paused in Areas Where BA.2 Is Dominant COVID-19 Variant
The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.


Related to this article

FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Measles Update: October 9, 2026
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
FAQ: What You Need to Know About Measles in 2026
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.